IPC to publish latest version of Indian Pharmacopoeia in June 2007
Gireesh P K, Mumbai

Indian Pharmacopoeia Commission (IPC) will be coming up with the new edition of Indian Pharmacopoeia, IP 2007, in June 2007.Though several addendums has made to the Indian Pharmacopoeia in due course of time, after 1996 it is the first time the Indian Pharmacopoeia Commission revamps the existing IP.

Several drugs in the present IP have become obsolete or lost its therapeutic relevance as of today and the new version is expected to maintain uniform standards of quality drugs and pharmaceuticals through out the country. The revised edition, draft of it has already made, will be in a user-friendly format and will have 1500 monographs covering a wide variety of therapeutic agents. It will add nearly 300 new monographs including active pharmaceutical ingredients (APIs), dosage forms and pharmaceutical excipients.

In an emailed reply to Pharmabiz, IPC member secretary-cum-scientific director Dr G N Singh said, "There have been faster and tremendous changes in analytical techniques of drugs and pharmaceuticals over the last few years. A lot of new drug formulations have been developed and are being marketed in India. Though the pharma industry is growing day-by-day, the Indian markets are still being hit by substandard quality of medicine as well as spurious drugs. The recent findings at IPC laboratory have revealed that many of the national survey samples (drugs and pharmaceuticals) do not conform to the quality specifications. The IPC's move is in line to maintain uniform standards of quality drugs and pharmaceuticals."

The new Pharmacopoeia will be in three hardbound volumes and a soft copy of the same in CD. Several monographs included in the new volume may not find in any other leading pharmacopoeias of the world. The timely publication of Indian Pharmacopoeia and its addenda for compliance by the stakeholders and regulatory bodies and certification and providing IP Reference Substances (IPCRS, IPBRS, IPPRS etc.) to the stakeholders are the challenges ahead for IPC, he said.

Commenting on the impact of new IP in the pharma industry G N Singh said, the new version of IP would boost the pharma industry in attaining uniform standards of quality and thereby raise their national and international status. It will also flourish the economic growth and development of the country in general and that of pharma industry in particular, he added.

Source: www.pharmabiz.com
17th May 2007

This Site is developed and maintained by Prashant H. Pandya
Site updated on Monday, May 21, 2007 5:15 PM
© Confederation of Indian Pharmaceutical Industry (ssi)